

BIOWORLD™ TODAY

THE DAILY BIOPHARMACEUTICAL NEWS SOURCE

August 16, 2016

Beyondspring Pharmaceuticals Inc., of New York, enrolled the first patient in China in the global phase III trial that is testing lead immuno-oncology asset, plinabulin, in second and third line non-small cell lung cancer in combination with docetaxel. The trial is expected to enroll 440 patients in China and 110 patients in the U.S. and other western countries.